This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.
This phase IV, open label, non-randomized, monocenter pharmacokinetic study will be carried out in critically ill and non-critically ill (hematology) patients receiving multiple dose treatment with L-AmB. The pharmacokinetic exposure to liposomal amphotericin B in plasma, urine, BAL and ascitic fluid will be compared between the two population groups in an early and late exposure day. Correlating covariates will be identified to provide a rationale for optimal dosing strategy in critically ill patients.
Study Type
OBSERVATIONAL
Enrollment
60
Plasma, urine, BAL and ascitic fluid sample collection.
UZ Leuven
Leuven, Belgium
RECRUITINGPlasma exposure and PK parameters
To document and compare plasma exposure and PK parameters in an ICU vs. non ICU hematology patient cohort in the early and late phase of L-AmB treatment.
Time frame: July 2020
Covariates
To document correlating covariates and to stimulate the pharmacokinetics of L-AmB to provide a rationale for optimal dosing strategy in critically ill patients.
Time frame: July 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.